Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Study Of Pregnancies Exposed to UCB Antiepileptic Drugs to Determine if There is a Potential Increase in the Risk of Major Birth Defects.

Next Previous
Search
Trial Profile

A Prospective Study Of Pregnancies Exposed to UCB Antiepileptic Drugs to Determine if There is a Potential Increase in the Risk of Major Birth Defects.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levetiracetam (Primary) ; Antiepileptic drugs
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors UCB

Most Recent Events

  • 01 Sep 2016 Status changed from active, no longer recruiting to completed.
  • 22 Dec 2015 Planned End Date changed from 1 Aug 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.
  • 22 Dec 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top